Posters & Publications
Talazoparib efficacy is enhanced by non-cytotoxic doses of Temozolomide-Mediated DNA damage in prostate cancer cell line.
Jeffrey N. Lindquist et al AACR DNA Repair: Tumor Development and Therapeutic Response Special Conference, November 2–5, 2016, Montreal, Quebec, Canada, Poster B30.
Download PDFTemozolomide analogs with improved brain/plasma ratios
Roopa Rai et al Bioorganic & Medicinal Chemistry Letters 26 (2016) 5103–5109.
Download PDFTargeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
Pradeep S. Jadhavar et al Bioorganic & Medicinal Chemistry Letters 26 (2016) 5222–5228.
Download PDFDiscovery of Pyrazolopyrimidine Derivatives as Novel Dual Inhibitors of BTK and PI3Kδ.
Brahmam Pujala et al ACS Medicinal Chemistry Letters7 (2016), 1161−1166.
Download PDFNovel 3-methylindoline inhibitors of EZH2: Design, synthesis and SAR.
Amantullah Ansari et al Bioorganic & Medicinal Chemistry Letters 27 (2017) 217–222.
Download PDFDiscovery of pyrazolopyrimidine derivatives as novel inhibitors of ataxia telangiectasia and rad3 related protein (ATR).
Sreekanth A. Ramachandran et al Bioorganic & Medicinal Chemistry Letters 27 (2017) 750 - 754.
Download PDFDesign, synthesis and optimization of bis-amide derivatives as CSF1R inhibitors
Sreekanth A. Ramachandran et al Bioorganic & Medicinal Chemistry Letters 27 (2017), 2153 – 2160.
Download PDFDual Inhibition of Bruton’s Tyrosine Kinase and Phosphoinositide-3-Kinase p110δ as a Therapeutic Approach to Treat Non-Hodgkin’s B Cell Malignancies.
Jennifer Alfaro et al J Pharmacol Exp Ther 361:312-321, May 2017.
Download PDF